Kidney Transplant Market Report 2026

The kidney transplant market size has grown strongly in recent years. It will grow from $6.42 billion in 2025 to $6.74 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to rising incidence of end-stage kidney disease, limited long-term effectiveness of dialysis, established success rates of kidney transplantation, growth in transplant center infrastructure, increasing awareness of transplant benefits.

The kidney transplant market size is expected to see strong growth in the next few years. It will grow to $8.31 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing demand for organ transplantation, advancements in immunosuppressive drug therapies, increasing adoption of expanded criteria donors, rising investment in transplant research, improving post-transplant survival rates. Major trends in the forecast period include increasing preference for kidney transplant over long-term dialysis, rising adoption of living-donor and paired kidney exchange programs, growing focus on post-transplant patient monitoring and care, expansion of pediatric kidney transplant procedures, improved outcomes through advanced immunosuppressive protocols.

The increasing prevalence of renal disorders and kidney failure is expected to drive the growth of the kidney transplant market in the coming years. Renal disorders and kidney failure occur when the kidneys stop functioning properly and are unable to regulate bodily chemicals or eliminate waste and excess water from the blood. Kidney failure often requires transplants to restore kidney function and address the root causes of the condition. For example, in 2023, the American Kidney Fund, a US-based non-profit organization, reported that 37 million Americans are affected by kidney disease. Consequently, the rising incidence of renal disorders and kidney failure is fueling the expansion of the kidney transplant market.

Major companies in the kidney transplant market are concentrating on creating advanced solutions, such as portable hypothermic perfusion systems, to improve donor kidney viability, enhance organ preservation during transport, and lower organ discard rates. A portable hypothermic perfusion system is a medical device that continuously circulates a cold, oxygenated preservation solution through a donor kidney, maintaining metabolism and tissue viability, unlike traditional static cold storage, where organs are placed on ice without active perfusion. For example, in January 2025, Paragonix Technologies, a U.S.-based medical device company, received U.S. Food and Drug Administration (FDA) clearance for the KidneyVault Portable Renal Perfusion System. The device represents a major advancement in kidney preservation, providing a fully mobile platform for end-to-end hypothermic perfusion during organ transport. It allows continuous, real-time monitoring of key perfusion parameters such as flow, pressure, and temperature, assisting clinicians in maintaining optimal organ quality from recovery to transplantation. This innovation promotes more consistent preservation, reduces risks associated with traditional static cold storage, and demonstrates the increasing focus on developing next-generation technologies to expand transplant readiness and enhance patient outcomes.

In September 2024, Getinge AB, a Sweden-based medical technology company, acquired Paragonix Technologies for around USD 477 million. Through this acquisition, Getinge obtains Paragonix’s advanced organ-preservation devices, digital tracking platforms, and transplant logistics expertise, enhancing its organ-transplant product portfolio and strengthening its global presence in kidney, liver, and pancreas preservation markets. Paragonix Technologies is a US-based provider of donor-organ preservation and transport systems, recognized for its FDA-cleared portable perfusion and cold-storage devices, including solutions for heart, lung, and kidney transplantation.

Major companies operating in the kidney transplant market are Pfizer Inc, Novartis AG, Astellas Pharma Inc, Veloxis Pharmaceuticals A/S, Bristol-Myers Squibb Company, Sanofi S.A., AbbVie Inc, Roche Holding AG, Merck & Co. Inc, Otsuka Pharmaceutical Co. Ltd, Hansa Biopharma AB, CareDx Inc, TransMedics Group Inc, Immucor Inc, Glycorex Transplantation AB, Alexion Pharmaceuticals Inc, CSL Behring Ltd, Grifols S.A., Kedrion Biopharma S.p.A., BioLife Solutions Inc.

North America was the largest region in the kidney transplant market in 2025.Europe is expected to be the fastest-growing region in the global kidney transplant market report during the forecast period. The regions covered in the kidney transplant market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney transplant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the kidney transplant market by increasing costs of imported surgical instruments, organ preservation solutions, and advanced patient monitoring devices. Transplant procedures and post-transplant care segments are most affected, particularly in North America and Europe due to reliance on cross-border medical device and pharmaceutical supply chains. Hospitals and transplant centers face higher procurement and operational costs, which may influence overall transplant expenses. However, tariffs have also encouraged local manufacturing of surgical tools, strengthened regional supply chains, and supported long-term resilience in transplant-related healthcare infrastructure.

The kidney transplant market research report is one of a series of new reports that provides kidney transplant market statistics, including kidney transplant industry global market size, regional shares, competitors with a kidney transplant market share, detailed kidney transplant market segments, market trends and opportunities, and any further data you may need to thrive in the kidney transplant industry. This kidney transplant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A kidney transplant is a surgical procedure in which a diseased or non-functioning kidney is replaced with a healthy kidney from a donor. It serves as a treatment option for individuals with end-stage kidney disease or severe kidney dysfunction that cannot be effectively managed with other therapies, such as dialysis.

The primary types of kidney transplants include deceased-donor kidney transplants, living-donor kidney transplants, and expanded-criteria donor kidney transplants. A deceased-donor kidney transplant involves obtaining a kidney from a deceased donor and transplanting it into a recipient with end-stage renal disease (ESRD). This procedure is carried out in both adult and pediatric patients and involves applications such as drug delivery, capsule endoscopy, and patient monitoring. These procedures are conducted by various end users, including transplant centers, hospitals, and academic and research institutes.

The kidney transplant market includes revenues earned by entities by providing post-transplant care and monitoring services, dialysis services, rehabilitation services, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.